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Cancer, epigenetics and the Nobel Prizes1. Editorial
The Nobel Prize in Physiology or Medicine 2012 have been
awarded jointly to Sir John B. Gurdon and Shinya Yamanaka
“for the discovery that mature cells can be reprogrammed to
become pluripotent” as it is described in the Nobel Prize web
site. Professors Gurdon and Yamanaka have all the merits to
be bestowed with such a prestigious award for their seminal
discoveries in the area. However, we can also consider this an-
nual prize as a recognition to Epigenetics, similarly to the
Nobel Prize of 2006 for Andrew Z. Fire and Craig C. Mello for
their of RNA interference - gene silencing by double-
stranded RNA. Reprogramming requires changing the epige-
nome of the cells and non-coding RNAs are critical elements
in the establishment of epigenetic patterns.
One definition of Epigenetics is “the transmitted inherited
genome activity that does not depend on the naked DNA se-
quence”. Epigenetics explainshow the samegenotype canpro-
duce different phenotypes as it occurs inmonozygotic twins or
cloned animals. There are several chemical modifications af-
fecting DNA, RNA, and proteins that constitute the epigenetic
setting, suchasDNAmethylation, histonemodifications, chro-
matin remodeling factors associated, nucleosome positioning
andnon-codingRNAactivity.Althoughthedisruptionof epige-
netic patterns might be behind the occurence of many human
disease, it is in cancerweremajor changeshavebeendescribed
and studied in detail. Human tumors undergo a global DNA
hypomethylation, which takes place mostly at endoparasitic
sequences andDNA-repetitive regions, and a promoter CpG is-
land hypermethylation of selected tumor suppressor tran-
scripts of coding genes (i.e. hMLH1, BRCA1 and p16Ink4a) and
microRNAs (i.e. miR-124a, miR-34B/c and miR-200 family)
(Heyn and Esteller, 2012). The accompanying reviews from
Jansson and Lund, 2012; Suzuki et al., 2012 dwell in the contri-
bution of microRNAs disruption to carcinogenesis and the un-
derstanding of the impact of DNA methylation in microRNA
transcriptional silencing in human tumors, respectively.
Froma translational standpoint, DNAmethylation has pro-
vided useful biomarkers for the correct diagnosis, prognosis
and prediction of chemosensitivity of malignancies (Heyn
and Esteller, 2012). For example, the initial finding of the pre-
dictor effect of MGMT hypermethylation in chemosensitivityfor alkylating drugs, the specificity of GSTP1 hypermethyla-
tion for the screening of prostate carcinoma and the observa-
tion that DNA hypermethylation changes were detectable in
biological fluids have generated many confirmatory follow-
up studies energized the biotech companies and driven sev-
eral clinical trials. The article by Nogueira da Costa and
Herceg (2012) describe the advantages and pitfalls of the epi-
genetic biomarkers. Among the most promising applications,
it is important to note the use of DNA methylation profiles in
the accurate diagnosis of Cancer of Unknown Primary
(Fernandez et al., 2012), a clinical oncology problemof growing
relevance.
DNAmethylationdoesnot act aloneand it is associatedwith
other epigenetic marks such as histone modifications. Histone
proteins are not only good-for packaging elements for DNA,
but also important to determine gene expression. It is a more
complicated scenario than DNA methylation because histone
have several isoforms,different aminoacid positions tomodify,
and several chemical groups (acetylation, methylation, phos-
phorylation, sumoylation, ubiquitination, etc.). Human tumors
display massive disruptions of the histone modification land-
scape such as a reduction of monoacetylated lysine 16 and tri-
methylated lysine 20 of histone H4, among others. In addition,
histonemodifiers are also target ofmutation/amplification/de-
letion in cancer: histone methyltransferases, demethylases,
deacetylases, acetyltransferases, etc. Barneda-Zahonero and
Parra, 2012 comment the particular involvement of histone
deacetylases in tumor formationandprogression.DNAmethyl-
transferases, TET proteins and microRNA processing machin-
ery enzymes are also targets of genetic disruption in
carcinogenesis. Furthermore, chromatin-remodeling proteins
arealso imbalancedanddefective incancercells, and thearticle
of Dr. Kumar, 2012 will be an eye-opener to realize about the
contribution of these last factors to cellular transformation.
Interestingly, pathological epigenetic marks are erasable
and we can externally intervene to change the landscape of
the epigenome: epigenetic proteins and marks are good tar-
gets for the development of new anticancer drugs. The ap-
proval of DNA demethylating agents and histone
deacetylase inhibitors for the treatment of leukemia and lym-
phoma patients was an awakening call for “Big Pharma” that
has placed epigenetics drugs in the crossroad of many
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specific and with limited success in solid epithelial tumors,
but the picture is fastly changing. In addition to an improved
molecular selection of sensitive patients for each type of
drug, new targets and compounds are appearing such as in-
hibitors for histonemethyltransferases, histone demethylase,
sirtuins, histone kinases, bromodomains or drugs that target
microRNAs. The manuscript by Nebiosso et al. (2012) explain
in detail the “state-of-the-art” in epigenetic clinical trials
and Hoffmann et al., 2012 whilst La Thangue, 2012 and
Hoffmann et al., 2012 focused in histone deacetlyase and his-
tone demethylases inhibitors, respectively.
Manyquestions remainopen in cancer epigenetics andnew
discoveries are made every week in this young and vigorous
field: the role of 5-hydroxymethylcytosine, the contribution
of non-coding RNAs beyond microRNAs such as antisense
RNAs (Guil et al., 2012), the function of long non-coding RNAs
such lincRNAs, theunderstandingof completedwholegenome
bisulfite sequencing samples, the relation between aging and
epigeneticmarks (Heyn et al., 2012), the analyses of single cells
using epigenomics...Stay tuned and enjoy the ride.R E F E R E N C E S
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